Pipeline - geneType

Leading the transition to precision medicine.

GeneType is leading the field of personalised, preventive medicine, also known as precision medicine. We are focused on developing the next generation of integrated predictive genetic testing and assessment tools – empowering medical practitioners and their patients to proactively manage health.


Coming Soon

GeneType Multi Test

A combination of geneType tests for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type 2 diabetes in a single test.

Know your risk of a serious disease to tailor a personalised prevention plan with your medical practitioner.

Our pipeline

We have a strong pipeline of tests covering a wide range of serious conditions that are currently in various stages development, accreditation and approval.

December 2020 - Consumer Tests Released for Breast Cancer and Colorectal Cancer

CIT platforms in AU and USA selling BRC and CRC

May 2021 - COVID19 Risk Test Release

IBX COVID risk test released for sale May 31, 2021

H2 2021 - Integration of Germline testing

100% Germline and PRS test for Breast Cancer and Colorectal Cancer to launch

H2 2021 - Multi Test Launch

Multi test to provide risk assessment for >70% of all comorbidities to launch

Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356

Keep up-to-date with our latest advances

Sign up to our newsletter to stay informed about our latest advances and how these could support you.